Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Avandia · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Avandia | DRUG | - |
Inclusion Criteria: * BMI 27-36 kg/m2 inclusive and at least two additional features of the metabolic syndrome or a first degree relative with a history of type 2 diabetes mellitus. BMI = Weight/height², (where weight is in kg, height in m). * Male or female aged 30 to 65 years, inclusive, at scree...
Avandia is a small molecule drug being developed for the treatment of insulin resistance, a metabolic condition. It is currently in Phase 3 clinical development and is being studied in patients with insulin resistance. The drug is intended to address this condition, though it remains investigational and has not been approved for this use.
Avandia is a small molecule drug being developed for insulin resistance. The specific molecular target of Avandia is not disclosed in the available information. The drug is being studied in a Phase 3 clinical trial to evaluate its effects on insulin resistance, a metabolic condition.
Avandia is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. GSK is conducting clinical research on Avandia for the treatment of insulin resistance, a metabolic condition. The drug is currently in Phase 3 development.
Avandia is in Phase 3 clinical development for the treatment of insulin resistance. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug is being evaluated for its safety and efficacy in patients with insulin resistance.
Avandia has one completed Phase 3 clinical trial with the identifier NCT00197132, titled "Study In Patients With Insulin Resistance." This trial enrolled 18 patients with insulin resistance in the Netherlands, with a minimum age of 30 years. The study was randomized, double-blind, and uncontrolled, and it has been completed.
Avandia is the brand name for the drug rosiglitazone, which is used to treat insulin resistance. However, the available information does not specify alternative names for Avandia. The drug is being developed by GSK plc and is currently in Phase 3 clinical trials for insulin resistance.